香港股市 已收市

BNTX Jan 2026 130.000 call

OPR - OPR 延遲價格。貨幣為 USD。
加入追蹤清單
11.000.00 (0.00%)
市場開市。 截至 09:35AM EDT。
全螢幕
前收市價11.00
開市11.00
買盤6.20
賣出價7.70
拍板130.00
到期日2026-01-16
今日波幅11.00 - 11.00
合同範圍
成交量20
未平倉合約85
  • Bloomberg

    BioNTech Cancer Drug Licensed From MediLink Faces FDA Delay

    (Bloomberg) -- The Food and Drug Administration delayed a breast- and lung-cancer trial of an experimental treatment that BioNTech SE licensed from Chinese biotech MediLink Therapeutics Ltd., citing safety concerns.Most Read from BloombergFlesh-Eating Bacteria That Can Kill in Two Days Spreads in JapanHow the US Mopped Up a Third of Global Capital Flows Since CovidThese Are the World’s Most Expensive Cities for Expats in 2024Ukraine Bid for Global South Support Falters at Swiss SummitSafeguards

  • Motley Fool

    Why Vaccine Stocks Rallied This Week

    A bird flu outbreak could spur demand for vaccines from these key players, but is it likely?

  • Benzinga

    European Patent Office Sides with Moderna In COVID-19 Vaccine Patent Dispute With Pfizer/BioNTech

    Moderna Inc (NASDAQ:MRNA) has reportedly achieved a significant victory at the European Patent Office (EPO) in its ongoing legal battle with Pfizer Inc (NYSE:PFE) and BioNTech SE (NASDAQ:BNTX) over the Covid-19 vaccine. The EPO’s Opposition Division upheld the validity of one of Moderna’s crucial patents, boosting the mRNA vaccine maker’s efforts to reclaim pandemic profits from its competitors, the Financial Times reports. Although Pfizer has nine months to appeal the decision, the EPO’s writte